The memory supplement guide: what the shelf contains and what works

A map, not a ranking. A family with better evidence is not a guarantee that a particular bottle in it contains a useful dose.

The most useful thing to know about that table is how different the four failure modes are. A botanical bottle usually fails on standardisation: two products naming the same plant can contain very different chemistry. A vitamin bottle usually fails on relevance: it works if you were short and does little if you were not. An amino acid bottle usually fails on dose, because the studied doses are measured in grams and capsules hold fractions of one.

A buyer who knows which failure mode they are facing can ask the one question that matters for that bottle. That is the whole purpose of this guide.

One family deserves a section of its own because it is the one most often explained badly. The vascular argument says that the brain is an enormously perfusion-hungry organ, that nitric oxide governs how wide small vessels sit, and that raising nitric oxide should therefore improve how the brain performs.

The first two steps are solid. the citrulline pharmacokinetic study showed oral L-citrulline raising plasma arginine dose-dependently, with 3 grams twice a day lifting even the trough concentration. the 2026 arginine blood pressure meta-analysis pooled five ambulatory blood pressure trials and found 24-hour systolic about 4.2 mmHg lower on oral arginine.

The third step is where it splits. the dietary nitrate cognition crossover gave healthy young adults 450 ml of beetroot juice supplying roughly 5.5 mmol of nitrate and found cerebral blood flow parameters and some cognitive measures shifting acutely. the 13-week nitrate dose trial ran thirteen weeks of incremental nitrate doses in overweight and obese older adults and found no change in cognition or cerebral blood flow at all.

Two well-conducted studies of the same pathway, opposite results, and the difference is the population and the duration. The honest reading is that the vascular route is real and its cognitive payoff is unsettled, particularly in the people most likely to be shopping for it.

Niacin is worth its own section because it is the only ingredient common on memory labels that has both a deficiency disease with a cognitive component and a modern research programme behind it.

The deficiency end is settled. Severe niacin deficiency produces pellagra, whose classical triad ends in dementia, and a 2026 pellagra case report is a recent case of exactly that picture reversing on treatment. the Chicago dietary niacin cohort then found, across 3,718 Chicago residents, that people in the upper quintiles of dietary niacin intake had roughly a third of the risk of incident Alzheimer's disease of the lowest quintile.

The modern programme tests the NAD idea directly, using nicotinamide riboside rather than niacin. the 2024 nicotinamide riboside trial randomised older adults with mild cognitive impairment to it, and the phase-II nicotinamide riboside pilot ran a phase-II pilot in amnestic mild cognitive impairment. Neither produced the decisive cognitive result the theory predicts, which is what an open question looks like from the inside.

So the fair statement is that NAD biology is one of the more promising lines in this field and that nobody has yet turned it into a capsule that demonstrably helps a healthy adult. Two sentences, and most sales pages write only the first.